Condition: Advanced Solid Tumor · Metastatic Breast Cancer · Metastatic Ovarian Cancer · Sponsor: EtiraRx Australia Pty Ltd
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
This description comes directly from the study's public registry record.
Research Director · 01 469 600 6603 · contact@etira.life
Always discuss trial participation with your own doctor first.
| Macquarie University Health | Ryde, New South Wales, Australia | Recruiting |
| The Kinghorn Cancer Center | Sydney, New South Wales, Australia | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Cancer Research SA | Adelaide, South Australia, Australia | Recruiting |
| Icon Cancer Centre Adelaide | Adelaide, South Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06533332